Get access

Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer

  • Protocol
  • Intervention

Authors

  • Gianpaolo Perletti,

    Corresponding author
    1. Università degli Studi dell'Insubria, Laboratory of Toxicology and Pharmacology, Biomedical Research Division, Dept. of Theoretical and Applied Sciences, Busto A, Province of Varese, Italy
    • Gianpaolo Perletti, Laboratory of Toxicology and Pharmacology, Biomedical Research Division, Dept. of Theoretical and Applied Sciences, Università degli Studi dell'Insubria, Via A. da Giussano, 10, Busto A, Province of Varese, 21052, Italy. gianpaolo.perletti@uninsubria.it.

    Search for more papers by this author
  • Vittorio Magri,

    1. Istituti Clinici di Perfezionamento, Urology/Urological Sonography Secondary Care Clinic, Milano, Italy
    Search for more papers by this author
  • Emanuela Marras,

    1. Dept. of Theoretical and Applied Sciences, Università degli Studi dell'Insubria, Laboratory of Toxicology and Pharmacology, Biomedical Research Division, Busto A, Lombardy, Italy
    Search for more papers by this author
  • Elena Monti,

    1. University of Insubria, Biomedical Research Division, Department of Theoretical and Applied Sciences, Varese, Italy
    Search for more papers by this author
  • Paul S Rennie,

    1. University of British Columbia, Vancouver Prostate Centre, Vancouver, British Columbia, Canada
    Search for more papers by this author
  • Alberto Trinchieri

    1. A. Manzoni Hospital, Urology Unit, Lecco, Italy
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the efficacy and toxicity of second-line therapies in the management of advanced, androgen deprivation-refractory prostate cancer in the post-docetaxel setting.

Get access to the full text of this article